Securities fraud class actions against life sciences companies increased by 65 percent in 2012 compared to 2011, reversing a previous dip, according to a new Dechert report.
Report: Life sciences securities cases increased in 2012
The National Law Journal
March 21, 2013
This article requires free registration
This article requires free registration to The National Law Journal. Please sign in or register to read the full text.